5′-O-(4,4′-Dimethoxytrityl)-N-acetyl-5-dimethylamino-2′-
deoxycytidine (6)
(4H), 6.26 (dd, 1H, J = 5.9, 6.0 Hz), 4.34 (t, 1H, J = 3.2 Hz),
3.88 (dd, 1H, J = 3.2, 6.8 Hz), 3.69 (s, 6H), 3.32 (dd, 1H, J =
3.4, 10.2 Hz), 3.12 (dd, 1H, J = 3,8, 10.6 Hz), 2.35 (s, 6H),
2.20–2.15 (1H), 2.05–1.98 (1H), 0.77 (s, 9H), −0.04 (6H); 13C
NMR (CDCl3, 400 MHz) δ 158.6, 149.0, 144.4, 135.5, 130.0,
129.1, 128.1, 127.9, 127.0, 113.2, 113.1, 86.4, 72.2, 62.9, 55.2,
42.3, 40.7, 25.6, 17.9, −4.7, −4.9; FABMS m/z 688 [(M+H)+];
HRMS calcd. for C38H50N3O7Si 688.3418, found 688.3412.
Tetrabutyl ammonium fluoride (1.0 M, 3.5 mL, 3.5 mmol) was
added to a solution of 5 (1.28 g, 1.76 mmol) in dry THF
(24 mL) and the mixture was stirred at room temperature for 1 h.
The reaction mixture was diluted with water and extracted with
ethyl acetate. The organic layer was washed with brine, dried
over Na2SO4, filtered, and concentrated. The crude product was
purified by column chromatography (SiO2, 5% methanol–chloro-
form) to give 6 (887 mg, 82%) as a yellow solid: 1H NMR
((CD3)2O, 400 MHz) δ 7.68 (s, 1H), 7.37–7.13 (9H), 6.74–6.71
(4H), 6.28 (t, 1H, J = 7.8 Hz), 4.49 (1H), 4.12 (1H), 3.79 (s,
6H), 3.43 (dd, 1H, J = 3.6, 10.4 Hz), 3.24 (dd, 1H, J = 3.4, 10.2
Hz), 2.53 (s, 3H), 2.44–2.41 (1H), 2.38 (s, 6H), 2.23–2.20 (1H);
13C NMR (CDCl3, 400 MHz) δ 158.7, 144.3, 135.5, 135.3,
130.1, 130.0, 128.1, 127.9, 127.1, 113.2, 113.1, 86.9, 86.5, 86.4,
72.3, 63.4, 55.2, 44.8, 41.9, 26.3, 25.6; FABMS m/z 615
[(M+H)+]; HRMS calcd. for C34H39N4O7 615.2819, found
615.2821.
3′-O-(tert-Butyldimethylsilyl)-5′-O-(4,4′-dimethoxytrityl)-5-
dimethylamino-2′-deoxycytidine (4)
A solution of 3 (1.94 g, 2.82 mmol), triethylamine (1.2 mL,
8.62 mmol), 4-dimethylaminopyridine (1.04 g, 8.46 mmol), and
2,4,6-triisopropylbenzenesulfonyl chloride (2.56 g, 8.46 mmol)
in anhydrous acetonitrile (24 mL) was stirred at room tempera-
ture for 16 h. The mixture was cooled in an ice bath. Aqueous
ammonia (28%, 35 mL) was added, and the mixture was stirred
for 3 h at ambient temperature. The reaction mixture was concen-
trated under reduced pressure and was taken up in ethyl acetate.
The organic layer was washed with brine, dried over Na2SO4,
filtered, and concentrated. The crude product was purified by
column chromatography (SiO2, 4% methanol–chloroform) to
give 4 (1.87 g, 97%) as a white solid: 1H NMR (CDCl3,
400 MHz) δ 7.55 (s, 1H), 7.54–7.23 (9H), 6.92–6.89 (4H), 6.46
(t, 1H, J = 6.8 Hz), 4.46 (dd, 1H, J = 6.6, 7.9 Hz), 4.05 (dd, 1H,
J = 3.0, 7.0 Hz), 3.87 (s, 6H), 3.57 (dd, 1H, J = 3.2, 10.8 Hz),
3.26 (dd, 1H, J = 3.2, 10.8 Hz), 2.55–2.49 (1H), 2.38 (s, 6H),
2.17–2.10 (1H), 0.89 (s, 9H), 0.03 (6H); 13C NMR (CDCl3,
400 MHz) δ 163.4, 158.6, 144.4, 135.7, 135.5, 130.1, 129.8,
128.2, 127.9, 127.0, 113.2, 113.1, 86.3, 85.9, 72.0, 62.7, 55.2,
44.2, 42.0, 25.7, 17.9, −4.7, −5.0; FABMS m/z 687 [(M+H)+];
HRMS calcd. for C38H51N4O6Si 687.3578, found 687.3580.
3′-(N,N-Diisopropylmethylphosphonamidite)-5′-O-(4,4′-
dimethoxytrityl)-N-acetyl-5-dimethylamino-2′-deoxycytidine (7)
Compound 6 was coevaporated twice with anhydrous acetonitrile
(1 mL). A solution of 6 (20 mg, 0.033 mmol), anhydrous diiso-
propylethylamine (16 μL, 0.10 mmol), and N,N-diisopropyl-
methylphosphonamidic chloride (7 μL, 0.033 mmol) in
anhydrous acetonitrile (350 μL) was stirred for 4 h at room temp-
erature. The reaction mixture was filtered and then placed on a
DNA synthesizer.
Synthesis of ODNs
ODNs containing 5-dimethylaminocytosine were synthesized on
an Applied Biosystems Model 3400 DNA/RNA synthesizer
using standard phosphoramidite chemistry. ODNs containing the
AQ sensitizer were prepared as in previously reported meth-
ods.18b ODN containing 5-aminocytosine was synthesized from
ODN1(BrC) (including 5-bromocytosine) as previously
reported.31 Synthesized ODNs were purified by reversed phase
HPLC on an Inertsil ODS-3 (ϕ 10 mm × 250 mm, elution with a
solvent mixture of 0.1 M triethylammonium acetate (TEAA) pH
7.0, linear gradient over 60 min from 0% to 30% acetonitrile at a
flow rate 3.0 mL min−1). The purity and concentration of
modified ODN were determined by complete digestion with calf
intestinal alkaline phosphatase, nuclease P1, and phosphodiester-
ase I. The synthesized ODNs were identified by MALDI–TOF
mass spectrometry (for ODN1(DMAC), AQ-ODN1(G),
AQ-ODN1(I), and ODN2(T/DMAC/T)) or ESI–TOF mass spec-
trometry (for ODN1(AmC), ODN1(MC), ODN1(BrC), AQ-ODN2
(A/G/A), AQ-ODN2(C/C/A), and AQ-ODN2(C/C/C)); ODN1
3′-O-(tert-Butyldimethylsilyl)-5′-O-(4,4′-dimethoxytrityl)-N-
acetyl-5-dimethylamino-2′-deoxycytidine (5)
A solution of 4 (1.87 g, 2.73 mmol), acetic anhydride (645 μL,
6.83 mmol), and 4-dimethylaminopyridine (167 mg, 1.37 mmol)
in anhydrous pyridine (27 mL) was stirred for 12 h at room
temperature. The reaction mixture was concentrated under
reduced pressure, diluted with water, and extracted with ethyl
acetate. The organic layer was washed with brine, dried over
Na2SO4, filtered, and concentrated. The crude product was
purified by column chromatography (SiO2, 50% ethyl acetate–
1
hexane) to give 5 (1.29 g, 65%) as a yellow solid: H NMR
(CDCl3, 400 MHz) δ 7.82 (s, 1H), 7.43–7.24 (9H), 6.84–6.81
(4H), 6.26 (t, 1H, J = 6.6 Hz), 4.40 (dd, 1H, J = 3,4, 7.0 Hz),
4.02 (dd, 1H, J = 3.6, 6.8 Hz), 3.79 (s, 6H), 3.54 (dd, 1H, J =
3.2, 11.6 Hz), 3.22 (dd, 1H, J = 3.4, 10.6 Hz), 2.71 (s, 3H),
2.58–2.53 (1H), 2.29 (s, 6H), 2.12–2.05 (1H), 0.82 (s, 9H),
−0.03 (6H); 13C NMR (CDCl3, 400 MHz) δ 158.7, 144.3,
135.5, 135.3, 130.1, 130.0, 129.1, 128.2, 127.9, 127.1, 113.2,
113.1, 86.7, 86.4, 71.7, 62.4, 44.8, 42.1, 25.7, 17.9, 4.7, −5.0;
FABMS m/z 729 [(M+H)+]; HRMS calcd. for C40H53N4O7Si
729.3684, found 729.3701.
(
(
DMAC) m/z 6241.48 (calcd. for [M − H]− 6240.15), ODN1
AmC) m/z 886.5 (calcd. for [M − 7H]7− 886.6) ODN1(MC) m/z
1034.2 (calcd. for [M − 6H]6− 1034.3), ODN1(BrC) m/z 1045.2
(calcd. for [M − 6H]6− 1045.1), AQ-ODN1(G) m/z 6390.21
(calcd. for [M − H]− 6389.17), AQ-ODN1(I) m/z 6375.04
(calcd. for [M − H]− 6374.05), ODN2(T/DMAC/T) m/z 5512.55
(calcd. for [M − H]− 5514.66), AQ-ODN2(A/G/A) m/z 1468.3
This journal is © The Royal Society of Chemistry 2012
Org. Biomol. Chem., 2012, 10, 2035–2043 | 2041